Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2024 | $30.00 | Buy | H.C. Wainwright |
| 4/2/2024 | $30.00 | Buy | Goldman |
| 3/7/2023 | Outperform | Evercore ISI | |
| 3/7/2023 | $39.00 | Buy | BofA Securities |
| 3/7/2023 | $32.00 | Buy | Guggenheim |
| 3/7/2023 | $27.00 | Overweight | Wells Fargo |
| 3/7/2023 | $45.00 | Buy | Stifel |
| 3/7/2023 | $40.00 | Outperform | Credit Suisse |
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results fo
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127International:1-201-689-8574Webcast:Link A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi
– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldost
SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results fo
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWebcast Link Stifel Healthcare Conference:Date:Tuesday, November 19, 2024Time:10:20am ESTFormat:Fireside ChatWebcast Link Evercore ISI HealthCONx ConferenceDate:Wednesday, December 4, 2024Time:4:15
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127International:1-201-689-8574Webcast:Link A live webcast of the conference call may also be found on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform
S-8 - Mineralys Therapeutics, Inc. (0001933414) (Filer)
144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
10-Q - Mineralys Therapeutics, Inc. (0001933414) (Filer)
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.67) by 4.48 percent. This is a 37.25 percent decrease over losses of $(0.51) per share from the same period last year.
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify
LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive